LGR5 and neoplasm: Using genetically engineered mouse models and organoid systems carrying mutations in APC, KRAS, TRP53, and SMAD4 to mimic stepwise CRC progression, de Sousa e Melo et al. [23] demonstrated that ablation of LGR5+ cells effectively restricts primary tumor growth but does not cause tumor regression.